KORU Medical Systems’ Q1 revenue growth and international expansion drove a 4.7% stock gain, with top-line results and strategic execution outperforming expectations despite modest near-term contributions from new assets.

• Revenue rose 22% year-over-year to $11.8 million, reflecting strength in recurring patient volumes and new patient diagnosis starts.
• Domestic core business grew 12%, fueled by legacy account retention and competitive conversions, maintaining momentum in the SCIg market.
• International revenue surged 35%, supported by prefilled syringe conversions in Europe and new market distributor orders.
• Progress continued on non-Ig pipeline assets with Phase III trial advancements and submission of a 510(k) for the Freedom Infusion System with deferoxamine.
• Management reiterated full-year guidance across revenue, margins, adjusted EBITDA, and cash flow, underscoring confidence in strategic priorities and sustainable profitability.